Key facts
- Notable investors include Xuhui Hi-Tech, Zhuzhou SAH Innovation & Entrepreneur Investment, I-Life Private Equity Fund Management, Wenzhou Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for CreatiPhage Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for CreatiPhage Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CreatiPhage Biotech
Developer of phage technology intended to stop drug-resistant bacteria from hiding a pandemic. The company focuses on human health, animal health and environmental interventions, it has developed a new generation of high-throughput intelligent screening systems, innovative drugs and personalized medical technologies based on natural phages and synthetic phages, providing comprehensive phage solutions that precisely target drug-resistant bacteria.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- cphage.com/
- Ownership
- Privately Held (backing)
CreatiPhage Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CreatiPhage Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CreatiPhage Biotech in its N-PORT filings yet. We sweep new filings monthly.